Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Bradley K Wong"'
Publikováno v:
Open Forum Infectious Diseases. 9
Background Epetraborole (EBO) is a boron-containing oral inhibitor of bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis; EBO demonstrates potent activity against nontuberculous mycobacteria. EBO is being developed for the tre
Autor:
Danna Jennings, Sarah Huntwork-Rodriguez, Anastasia G. Henry, Jennifer C. Sasaki, René Meisner, Dolores Diaz, Hilda Solanoy, Xiang Wang, Elvira Negrou, Vitaliy V. Bondar, Rajarshi Ghosh, Michael T. Maloney, Nicholas E. Propson, Yuda Zhu, Romeo D. Maciuca, Laura Harris, Angela Kay, Peter LeWitt, T. Alex King, Drew Kern, Aaron Ellenbogen, Ira Goodman, Andrew Siderowf, Jason Aldred, Omid Omidvar, Shababa T. Masoud, Sonnet S. Davis, Annie Arguello, Anthony A. Estrada, Javier de Vicente, Zachary K. Sweeney, Giuseppe Astarita, Marie T. Borin, Bradley K. Wong, Harvey Wong, Hoang Nguyen, Kimberly Scearce-Levie, Carole Ho, Matthew D. Troyer
Publikováno v:
Science Translational Medicine. 14
Mutations in leucine-rich repeat kinase 2 ( LRRK2 ) are the most common genetic risk factors for Parkinson’s disease (PD). Increased LRRK2 kinase activity is thought to impair lysosomal function and may contribute to the pathogenesis of PD. Thus, i
Publikováno v:
Handbook of Drug Metabolism ISBN: 9780429190315
Advances in the mechanistic knowledge of drug metabolism enzymology are enabling the early-stage understanding of clearance pathways that can be applied in designing clinical pharmacology programs. Clinical drug metabolism studies provide definitive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::578ea6feede4202f0d862d4b0c734a78
https://doi.org/10.1201/9780429190315-20
https://doi.org/10.1201/9780429190315-20
Autor:
Guifen Xu, Daqing Sun, Wotang T Huang, Yun Ling, Bradley K. Wong, Min Jiang, Lixia Jin, Xuelei Yan, Steven H. Olson, Qiuping Ye
Publikováno v:
Xenobiotica. 45:681-692
1. AMG 232 is a novel inhibitor of the p53-MDM2 protein-protein interaction currently in Phase I clinical trials for multiple tumor indications. The objectives of the investigations reported in this article were to characterize the pharmacokinetic an
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 46(11)
1. The utility of two abbreviated, higher-throughput assays [IC50-shift and the loss of activity (LOA) assay] to evaluate time-dependent inhibition (TDI) of 24 structurally related compounds was compared. 2. Good correlation (R(2) = 0.90) between % i
Autor:
Bradley K. Wong, Yun Ling, Adria E. Colletti, Liyue Huang, Jonathan Roberts, Eskouhie Tchaparian, Xuhai Be, Meghan Langley, Lixia Jin
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 343:316-324
This study was designed to characterize breast cancer resistance protein (Bcrp) knockout Abcg2(-/-) rats and assess the effect of ATP-binding cassette subfamily G member 2 (Abcg2) deletion on the excretion and pharmacokinetic properties of probe subs
Autor:
C. Charles Lin, Jiunn H. Lin, James A. Yergey, Wei Tang, A. David Rodrigues, Bradley K. Wong, Ping Lu, Thomas A. Baillie, Jason S. Ngui, Qin Mei, Cuyue Tang, Rominder Singh, Thomas H. Rushmore, Paul G. Pearson, Dan Cui, Yuh Lin, Magang Shou
Publikováno v:
Current Drug Metabolism. 2:17-36
The most common drug-drug interactions may be understood in terms of alterations of metabolism, associated primarily with changes in the activity of cytochrome P450 (CYP) enzymes. Kinetic parameters such as K m , V max , K i and K a , which describe
Autor:
George Tonn, Raju Subramanian, Bradley K. Wong, Simon Wong, Peter W. Fan, Michael G. Johnson, Michelle Tadano Lohr, Kirk Henne
Publikováno v:
Drug Metabolism and Disposition. 38:841-850
The 2-methyl substituted indole, 2MI [2-(4-(4-(2,4-dichlorophenylsulfonamido)-2-methyl-1 H -indol-5-yloxy)-3-methoxyphenyl)acetic acid] is a potent dual inhibitor of 1) chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells a
Autor:
Bradley K. Wong, Bettina Van Lengerich, Sylvia C. Wong, Andrew P. Marcus, Paul G. Pearson, Xuemei Wang, Leslie C. Floren, Karen Berry, Robert Cho, George Tonn, Julio C. Medina, Simon Wong, Kathryn Kersey, Ji Ma, Michael G. Johnson
Publikováno v:
Drug Metabolism and Disposition. 37:502-513
(R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]-pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxyphenyl)-acetamide (AMG 487) is a potent and selective orally bioavailable chemokine (C-X-C motif) receptor 3 (CXCR3) antag
Autor:
Samuel L. Graham, James Z. Deng, Diem N. Nguyen, Victor K. Johnston, James C. Hershey, Bradley K. Wong, Christopher A. Salvatore, Cynthia Miller-Stein, Kenneth S. Koblan, Christopher S. Burgey, Scott D. Mosser, Daniel V. Paone, Stefanie A. Kane, Anthony W. Shaw, Theresa M. Williams, Joseph P. Vacca
Publikováno v:
Journal of Medicinal Chemistry. 50:5564-5567
Calcitonin gene-related peptide (CGRP) has been implicated in the pathogenesis of migraine. Herein we describe optimization of CGRP receptor antagonists based on an earlier lead structure containing a (3R)-amino-(6S)-phenylcaprolactam core. Replaceme